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Purpose: Endoscopic submucosal dissection (ESD) is a technically difficult and 
lengthy procedure requiring optimal depth of sedation. The bispectral index (BIS) 
monitor is a non-invasive tool that objectively evaluates the depth of sedation. The 
purpose of this prospective randomized controlled trial was to evaluate whether 
BIS guided sedation with propofol and remifentanil could reduce the number of 
patients requiring rescue propofol, and thus reduce the incidence of sedation- and/
or procedure-related complications. Materials and Methods: A total of 180 pa-
tients who underwent the ESD procedure for gastric adenoma or early gastric can-
cer were randomized to two groups. The control group (n=90) was monitored by 
the Modified Observer’s Assessment of Alertness and Sedation scale and the BIS 
group (n=90) was monitored using BIS. The total doses of propofol and remifent-
anil, the need for rescue propofol, and the rates of complications were recorded. 
Results: The number of patients who needed rescue propofol during the procedure 
was significantly higher in the control group than the BIS group (47.8% vs. 
30.0%, p=0.014). There were no significant differences in the incidence of seda-
tion- and/or procedure-related complications. Conclusion: BIS-guided propofol 
infusion combined with remifentanil reduced the number of patients requiring res-
cue propofol in ESD procedures. However, this finding did not lead to clinical 
benefits and thus BIS monitoring is of limited use during anesthesiologist-directed 
sedation.
Key Words:   Bispectral index, endoscopic submucosal dissection, propofol, remi-
fentanil
INTRODUCTION
Therapeutic endoscopic procedures requiring sedation of the patient have become 
popular worldwide. Endoscopic submucosal dissection (ESD) is a new and mini-
mally invasive method for the resection of early gastric cancers and gastric adeno-
mas that allows for en-bloc resection and an accurate histological evaluation.1,2 
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cholangiopancreatography (ERCP), BIS monitoring of pro-
pofol-induced deep sedation has been reported to reduce 
the mean propofol dose and recovery times.16,17 However, 
studies evaluating the clinical usefulness of BIS monitoring 
for gastrointestinal endoscopy have shown inconsistent re-
sults with regards to the dose of sedatives, satisfaction scores, 
and the risk of complications.14-19 Furthermore, the evi-
dence is limited regarding the effects of BIS monitoring on 
the clinical benefit of the stable maintenance of optimal se-
dation during ESD procedures using propofol infusion with 
opioids. Therefore, in this prospective randomized con-
trolled trial, we evaluated whether BIS monitoring for tar-
get sedation using continuous propofol infusion along with 
remifentanil could reduce the number of patients requiring 
rescue propofol, as well as the incidence of sedation- and/or 
procedure-related complications.
MATERIALS AND METHODS
　　　
The study received Institutional Review Board approval 
(ref. 4-2011-0347) and was registered at http://clinicaltrials.
gov (registration number NCT01921283). After obtaining 
written informed consent from each patient, we studied 180 
patients who were scheduled for elective ESD. The inclu-
sion criteria were adult patients aged 20--80 with American 
Society of Anesthesiologists classifications of 1--3. The ex-
clusion criteria were as follows: a body mass index (BMI) 
>35 kg/m2, severe hepatic (liver transaminase >100 IU/L) 
or renal (serum creatinine level >2 mg/dL) insufficiency, 
mental incompetence, a history of allergy to the study 
drugs, use of antidepressants or anticonvulsants, unstable 
angina, symptomatic congestive heart failure, symptomatic 
chronic obstructive pulmonary disease, baseline oxygen 
saturation <90% on room air, and baseline systolic blood 
pressure <80 mm Hg. 
Patients were randomly assigned to either the control 
group (n=90) or the BIS group (n=90) by the opening of a 
sealed allocation envelope. Our goal of sedation was to 
achieve sedation between moderate (patient responds prop-
erly to verbal or light tactile stimulation) and deep (patient 
respond to painful stimuli; airway support may be required) 
levels.4 All sedation was managed by an anesthesiologist 
who had more than four years of general anesthesia experi-
ence before study enrollment. The target level of sedation 
was monitored by the Modified Observer’s Assessment of 
Alertness and Sedation (MOAA/S) scale (Table 1) in the 
However, ESD is a technically difficult procedure requiring 
a longer procedure time than conventional endoscopic mu-
cosal resection.3 Moreover, patients experience discomfort 
and pain caused by rotation of the scope, overextension of 
the gastric wall, and the ripple effect of direct heat coagula-
tion of the muscularis.4 Although general anesthesia is rare-
ly considered in difficult cases requiring a high level of 
technical expertise,4 sedation for ESD is usually carried out 
as a safe and cost-effective method. Therefore, the optimal 
depth of sedation is important not only to improve facility 
efficiency and patient cooperation, but also to avoid proce-
dure-related complications such as perforation caused by 
sudden body movements.4-6
Sedation for ESD using propofol has been shown to pro-
vide better sedation effectiveness, safety, and improved re-
covery profile, compared to midazolam.7-9 Additionally, the 
combined use of analgesics is recommended for ESD to re-
lieve pain. Adding opioids has been reported to improve the 
quality of sedation and reduce the propofol dosage and in-
terventions required during the endoscopic procedures.4,10,11 
However, due to the narrow therapeutic range and the syn-
ergistic effect of the drugs, especially in complex and pro-
longed endoscopic procedures, the combined use of propo-
fol and opioids may lead to oversedation, resulting in a high 
risk of cardiopulmonary complications.10,12 Therefore, the 
precise monitoring of the level of sedation is warranted in 
order to minimize the risks of cardiopulmonary compro-
mise during the moderate-to-deep sedation required for 
ESD procedures.4
The bispectral index (BIS) monitor is a non-invasive tool 
that objectively evaluates the depth of sedation, and can be 
contrasted with conventional observational assessments 
during therapeutic endoscopic procedures that are based on 
somatic responses.8,13-17 BIS monitoring of moderate-to-
deep sedation using propofol during ESD procedures was 
associated with a high satisfaction level of patients and en-
doscopists.14 In patients undergoing endoscopic retrograde 
Table 1. Modified Observer’s Assessment of Alertness/Se-
dation Scale 
Score Responsiveness
5 Responds readily to name spoken in a normal tone
4 Lethargic response to name spoken in a normal tone
3
Responds only after name is called loudly and/or 
  repeatedly
2 Responds only after mild prodding or shaking
1 Responds only after painful trapezius squeeze
0 No response after painful trapezius squeeze
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according to the target level of sedation; to simulate the cur-
rent situation in Korea, a target-controlled infusion system 
was not used. In patients with BMI >25 kg/m2, sedation 
doses were calculated based on body weight for a BMI of 
25. If procedural interference occurred, 0.4 mg/kg of pro-
pofol (rescue propofol) could be given as a bolus by the at-
tending anesthesiologist in either group. Procedural inter-
ference was defined as a temporary pause in the procedure 
or need to physically restrain the patients due to sudden 
body movements or insufficient cooperation. Propofol and 
remifentanil infusion were continued until the removal of 
the endoscope.
After the procedure, patients were transferred to the endos-
copy unit recovery room for post-procedure monitoring. An 
Aldrete recovery scoring system was used to determine the 
appropriateness (a score of 8 out of 10) for discharge from 
the recovery room judged by the postanesthesia care unit 
nursing staff who were not involved in the study. Satisfac-
tion among the physicians and patients with the sedation and 
the procedure was recorded using an 11-point scale (0--10) 
after the end of the procedure and before discharge from 
the endoscopy unit recovery room, respectively. All patients 
also completed a questionnaire about pain and/or discom-
fort using a visual analog scale (VAS), ranging from 0 mm 
(no pain) to 100 mm (worst pain imaginable) (Fig. 1), and 
recall of the procedure before discharge from the endosco-
py unit recovery room. 
Adverse events and management 
Cardiopulmonary events such as bradycardia (HR <45 beats/ 
min), hypotension (systolic BP <80 mm Hg), and desatura-
tion (SpO2 <90% of any duration) were recorded during the 
ESD procedure and recovery room care. When an adverse 
event occurred, the following measures were undertaken: 
atropine 0.01 mg/kg IV for bradycardia, the reduction of 
the maintenance dose of propofol and 0.9% saline 300 mL 
loading with/without 4 mg of ephedrine for hypotension. If 
desaturation <90% developed, supplemental oxygen flow 
control group and using BIS values in the BIS group. In the 
control group, our target level of sedation corresponds to a 
score of 1--2 on the MOAA/S (i.e., patient responds only af-
ter squeezing the trapezius; responds only after mild prod-
ding or shaking), which was routinely evaluated at 1 minute 
after propofol administration, just before endoscopy inser-
tion, submucosal inflation by epinephrine (1:100000) and 
submucosal dissection, and when patients did not cooper-
ate. In the BIS group, the sedation level was assessed based 
on a BIS score of 68--75.20 All patients were given supple-
mental oxygen of 2 L/min by a nasal cannula throughout the 
procedure.
Monitoring and medication
All patients were continuously monitored for heart rate 
(HR), peripheral oxygen saturation (SpO2), and electrocar-
diographic changes. Blood pressure (BP) was assessed au-
tomatically at 5-minute intervals and all vital signs were re-
corded at 5-minute intervals. In all patients, a single use, 
disposable, low impedance BIS sensor consisting of four 
electrodes was attached to the middle and right forehead. 
However, only patients allocated in the BIS group were mon-
itored by Bispectral Index (BIS VISTA Monitoring System; 
Aspect Medical Systems Inc., Norwood, MA, USA), which 
was placed behind endoscopists. Endoscopists and patients 
were blinded to the assigned group throughout the study. 
All procedures were performed with a standard single chan-
nel endoscope in the left lateral decubitus position. The pro-
cedure involved marking, mucosal incision, and submuco-
sal dissection with simultaneous hemostasis. 
All patients were premedicated with butylscopolamine 
(Buscopan®; Handok Pharm. Co., Cheongju, Korea) and 
received propofol and remifentanil using total body weight 
for sedation and analgesia. Sedation was initiated with 0.8 
mg/kg of propofol and 30 mg of lidocaine; thereafter, 3 mg/
kg/hr of propofol and 3 µg/kg/hr of remifentanil were start-
ed using an infusion pump and maintenance doses of pro-
pofol were titrated by 0.5 mg/kg/hr in a stepwise manner 
(mm)
Fig. 1. Visual analog scale ranged from 0 mm (no pain) to 100 mm (worst pain imaginable).
No pain Mild Moderate Severe
Worst pain
imaginable
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90 patients would be required for each group. All statistical 
analyses were performed with the SPSS 18.0 (SPSS Inc., 
Chicago, IL, USA) program. A p value <0.05 was consid-
ered statistically significant.
RESULTS
 
This study included a total of 220 lesions in 180 patients 
who underwent the ESD procedure for gastric adenoma or 
early gastric cancer from May 2011 to February 2012. The 
baseline characteristics were similar between the groups 
(Table 2). The mean age was 62.5 years and the age range 
was 38--80 years.
There were no significant differences in the time from the 
end of endoscopy until eye opening, the time from endosco-
py until leaving the recovery room, the total dose and mean 
maintenance rate of propofol, and the total dose of remifen-
tanil between the two groups (Table 3). The number of pa-
tients who needed rescue propofol during the procedure was 
significantly higher in the control group than the BIS group 
(47.8% vs. 30%). The frequency of sudden body move-
ments did not differ between the control group and the BIS 
group (31.1% vs. 22.2%). There were no significant differ-
ences in the satisfaction scores of the physicians and pa-
tients between the two groups. There were 54 (60%) pa-
tients in the control group and 58 (64.4%) patients in the 
BIS group who experienced discomfort after awakening in 
the endoscopy unit recovery room; their VAS scores were 
was increased until the saturation reached 95%. If desatura-
tion <90% continued despite increased supplemental oxy-
gen flow, the procedure and sedation were interrupted to se-
cure the airway. Complications including gastric bleeding, 
perforation, and aspiration pneumonia were observed dur-
ing the hospital stay. Incidents of bleeding, defined as intra- 
and post-procedural bleeding requiring packed red blood cell 
transfusion or endoscopic intervention, perforation showing 
direct endoscopic observation of mesenteric fat or free air 
on an abdominal radiograph or computed tomography scan, 
and aspiration pneumonia showing pneumonic consolida-
tion on chest radiograph were recorded until the patient’s 
discharge from the hospital.
Statistical analysis 
All data are expressed as means±standard deviations, num-
bers (percentages), or medians (upper and lower quartiles), 
as appropriate. Data between the groups were compared us-
ing the χ2 test, Fisher exact test, independent t-test, or the 
Mann-Whitney U test, as appropriate. To assess data normal-
ity, the Kolmogorov-Smirnov test was performed on the data 
set. In the preliminary trial of 36 patients, the number of pa-
tients requiring rescue propofol was 9 and 5 in the control 
group and the BIS group, respectively. We accepted that a 
50% reduction in the proportion of patients with rescue pro-
pofol intervention represented a clinically significant benefit. 
According to a preliminary study, 85 patients would be re-
quired in each group with a power of 0.9 and a type I error of 
0.05. Factoring in a drop-out rate of --5%, we calculated that 
Table 2. Demographic Characteristics
Control group (n=90) BIS group (n=90) p value
Age (yrs) 63.3±8.4 61.7±9.3 0.236
Female 61 (67.8) 68 (75.6) 0.247
Wt (kg) 64.4±9.9   65.7±10.7 0.374
BMI (kg/m2) 24.1±2.8 24.5±3.1 0.413
Comorbidities 
    Cardiovascular disease 23 (25.6) 23 (25.6) 1.000
    Lung disease 1 (1.1) 4 (4.4) 0.368
    Diabetes 14 (15.6) 10 (11.1) 0.380
ASA 0.951
    1 56 (62.2) 54 (60.0)
    2 30 (33.3) 32 (35.6)
    3 4 (4.4) 4 (4.4)
Baseline oxygen saturation (%) 99.3±1.3 99.4±1.1 0.327
Baseline heart rate (beats/min)   82.6±16.2   79.4±12.9 0.217
Baseline systolic blood pressure (mm Hg) 130.2±21.9 132.1±23.4 0.589
BIS, bispectral index; ASA, American Society of Anesthesiologists; BMI, body mass index.
Values are number of patients (%) or means±SD. 
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groups with regard to the incidence of complications and 
recall of the procedure (Table 5). Overall cardiopulmonary 
events during sedation and recovery room care were ob-
served in 22 patients (24%) in the control group and in 22 
patients (24%) in the BIS group (p=1.00). Oxygen desatura-
tion and hypotension during sedation occurred in 14 patients 
29±17 and 27±12 in the control and BIS group, respective-
ly. There were no differences in the locations of the lesions 
and the resection sizes (Table 4). Hemodynamic variables 
including HR and mean BP did not differ between the two 
groups (Fig. 2).
There was no significant difference between the two 
Table 3. Sedation Data 
Control group (n=90) BIS group (n=90) p value
Time from end of endoscopy until eye opening (min)  2.0±2.4   2.1±2.1 0.830
Time from end of endoscopy until leaving recovery room (min)  21.4±13.6 18.8±5.7 0.117
Total dose of propofol (mg)  292±186   308±166 0.549
Mean maintenance rate of propofol (mg/kg/hr)  3.8±0.9   4.1±0.6 0.059
Number of patients requiring rescue propofol 43 (47.8) 27 (30.0)* 0.014
Total dose of remifentanil (μg)  158±127 157±99 0.980
Input during procedure (mL)  402±300   417±276 0.722
Physician satisfaction score  8.2±1.4   8.3±1.3 0.639
Patient satisfaction score  8.7±1.3   8.9±1.0 0.475
BIS, bispectral index.
Values are numbers of patients (%) or means±SD. 
*p>0.05 compared with control group. 
Table 4. Endoscopic Data
Control group (n=90) BIS group (n=90) p value
Number of lesions 107 103
Lesion 0.800
    Cancer 48 (44.9) 48 (46.6)
    Adenoma 59 (55.1) 55 (53.4)
Location in stomach 0.681
   Upper 2 (1.9) 4 (3.9)
   Middle 34 (31.8) 32 (31.1)
   Lower 71 (66.4) 67 (65.0)
Size of resection (mm) 33.1±6.9 34.7±10.8 0.248
Procedure duration (min)       35.0 (25.0--60.0)       44.0 (28.8--60.0) 0.298
BIS, bispectral index.
Values are numbers of patients or means±SD or median (interquartile range). 
Fig. 2. Hemodynamic data including heart rate (A) and mean blood pressure (B) during the procedures. Data are expressed as mean±SD. No differences be-
tween the groups. BIS, bispectral index.
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administered. 
During ESD procedures, the stable maintenance of optimal 
levels of sedation is mandatory to minimize the risk of perfo-
ration and other procedure-related complications caused by 
uncontrolled body movement.4 Recently, propofol-induced 
moderate-to-deep sedation for ESD has been reported to be 
as safe and effective as benzodiazepine with better recovery 
profiles.7-9 Adding analgesics is also recommended for ESD 
to relieve pain and to improve the quality of sedation.4,10,11,21 
Combined continuous propofol infusion and opioid admin-
istration has been reported to improve ESD performance, 
with benefits such as en bloc resection and complete resec-
tion, compared to intermittent midazolam/propofol injec-
tion methods.21 However, considering that sedation level is 
a continuum, the moderate-to-deep or deep sedation re-
quired for ESD procedures may increase the patient’s risk 
of complications caused by excessive sedation, as deep se-
dation is highly associated with inadequate ventilation or 
airway obstruction.4,7-9,14 Additionally, continuous propofol 
infusion with opioids for moderate-to-deep sedation, lengthy 
procedure times >2 hr, the male gender, and age >75 years 
have been reported to be independent risk factors for pneu-
monia after ESD.22 According to the guidelines for sedation 
and/or analgesia by non-anesthesiologists, the accurate ti-
tration of drugs and close communication between the pa-
tient and the physician are recommended to achieve a high 
quality of mild-to-moderate sedation for diagnostic or ther-
apeutic procedures.23,24 However, in cases requiring more 
than moderate depths of sedation for ESD, monitoring 
mainly relies on the direct observation of the patients’ be-
(8%) and 27 patients (15%), respectively. Patients who ex-
perienced desaturation more than 60 seconds were one in 
the control group and three in the BIS group (p=0.621). 
There was no case of desaturation needing intubation or 
ventilation. There was also no case of sustained hypotension 
after propofol titration and saline loading in either group. 
The overall complications, including perforation, gastric 
bleeding, and aspiration pneumonia, were observed in 13 
patients (14%) in the control group and in 7 patients (8%) 
in the BIS group (p=0.16). Perforation related to ESD oc-
curred in 3% of patients after ESD; all perforations were 
managed with fasting and observation. Only one patient ex-
perienced both perforation and gastric bleeding. None of 
these patients underwent additional surgery due to perfora-
tion and gastric bleeding. There was no ESD-related mor-
tality throughout the study period.
DISCUSSION
In this prospective randomized controlled trial to investigate 
the efficacy of BIS as a monitor of sedation in ESD, we 
found that BIS monitoring as the primary target for sedation 
using a combination of propofol and remifentanil led to a re-
duction in the number of patients requiring rescue propofol. 
However, this finding, suggesting more stable maintenance 
within the range of the target depth of sedation by BIS moni-
toring than by MOAA/S, was not associated with clinical 
benefits in terms of the incidence of sedation- and/or proce-
dure-related complications and the total dose of propofol 
Table 5. Adverse Events and Hospital Stay
Control group (n=90) BIS group (n=90) p value
Cardiopulmonary events during sedation
    Desaturation 15 (16.7)   9 (10.0) 0.188
    Hypotension 13 (14.4) 14 (15.6) 0.835
    Bradycardia 0 0 1.000
No. of desaturation events per patients 0.339
    1 13 (14.4) 7 (7.8)
    2 1 (1.1) 2 (2.2)
    3+ 1 (1.1) 0
Recall of procedure 7 (7.8) 3 (3.3) 0.193
Complications
    Perforation 5 (5.6) 1 (1.1) 0.211
    Delayed bleeding 4 (4.4) 3 (3.3) 1.000
    Aspiration pneumonia 5 (5.6) 4 (4.4) 1.000
Length of hospital stay (day) 4.9±1.6 4.8±2.4 0.889
BIS, bispectral index.
Values are numbers of patients (%) or means±SD. 
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safety of patients in most countries. In the current study, the 
experienced anesthesiologists might have more quickly rec-
ognized restless movements in patients and thus influence 
the results so that the satisfaction scores of both patients 
and physicians did not differ between the two groups. In 
contrast to studies where propofol was administered by re-
peated bolus injection,16,18 we used continuous infusion 
method for a steady plasma level and consequently main-
tained a stable target depth of sedation, which may result in 
rapid recovery in both groups.
As well, we chose to use remifentanil in combination with 
propofol to improve the quality of sedation and thus ESD 
performance through the attenuation of responses to nox-
ious stimuli.10,21,27 The analgesic properties of propofol for 
countering acute pain remain controversial and thus remi-
fentanil, with its fast onset and short duration, may be a 
suitable analgesic adjunct in ESD patients. Adding remifen-
tanil reduces the needed concentration of propofol to ablate 
responses to noxious stimuli because the interaction be-
tween propofol and remifentanil is synergistic. In the current 
study, adding remifentanil partially blocked the response to 
pain and thus might contribute to the prevention of proce-
dure-related complications in either group. In consideration 
of the pharmacodynamic interaction between propofol and 
remifentanil in hypnosis and BIS, it was found that while 
propofol was equipotent in its effect on BIS with/without 
remifentanil, remifentanil had little direct effect on BIS but 
influenced BIS through the potentiation of the hypnotic ef-
fect of propofol.25 Regardless of the addition of remifent-
anil, BIS has been reported to be reliable for assessing the 
patient’s level on the Observer’s Assessment of Alertness/
Sedation Scale.28
This study has several limitations. First, the attending an-
esthesiologist was not blind to the use of BIS monitoring 
during ESD, a condition that was not possible in our study 
design. Second, we did not plan to evaluate the time lag be-
tween the signal collection and BIS display, which varies 
depending on the smoothing and processing of the artifact-
free signal.29 However, this time lag in the BIS group would 
not have a large effect on the results because the attending 
anesthesiologist recognized the changing trend of the BIS 
values and maintained the patient’s anesthesia within the 
target values of BIS. Third, although the sample size was 
calculated to validate the proportion of patients requiring 
rescue propofol, the power to assess the incidence of seda-
tion- and/or procedure-related complications was not suffi-
cient. Finally, we administered propofol and remifentanil 
haviors or responses to voice and physical stimuli through 
the MOAA/S. Therefore, the use of BIS for quantifying the 
effects of hypnotic drugs has been studied for the continuous 
monitoring of propofol sedation for therapeutic endoscopic 
procedures.14,16,17 However, studies evaluating the efficacy of 
BIS monitoring for propofol sedation in gastrointestinal en-
doscopy have shown inconsistent results.14,16-19 While BIS is 
clinically used as a measure of the depth of sedation, the 
BIS algorithm actually reflects the brain’s response to both 
the effects of the hypnotic drugs and noxious stimuli. Thus, 
proper interpretation of BIS needs to consider the drugs 
used, the administration methods of the drugs, and levels of 
noxious stimuli.25,26
To our knowledge, this is the first study to investigate the 
efficacy of BIS monitoring during anesthesiologist-directed 
propofol and remifentanil sedation for ESD procedures. In 
the current study, BIS monitoring as the primary target for 
sedation by the continuous infusion of both propofol and 
remifentanil reduced the number of patients requiring rescue 
propofol. Rescue propofol was administered for patient 
safety as a bolus injection in cases of procedural interference 
due to sudden body movement or insufficient patient coop-
eration by the attending anesthesiologist. Our results suggest 
that BIS monitoring was more nimble than MOAA/S moni-
toring in titrating the maintenance rate of propofol accord-
ing to the response to different noxious stimuli, but was not 
related to reduction in procedure-related complications such 
as bleeding and perforation. In previous endoscopic studies 
regarding BIS monitoring of propofol sedation, BIS moni-
toring has shown clinical benefits such as improved satis-
faction levels of patients and physicians after ESD,14 re-
duced mean propofol dose in ERCP,17 and shorter recovery 
times after ERCP.16 Although the clinical efficacy of BIS 
monitoring in decreasing rescue propofol did not lead to a 
reduction in total dose of propofol, studies from other groups 
have demonstrated no advantage for BIS monitoring in 
terms of propofol dose.14,16 Direct comparison of our results 
with previous studies is rather difficult because of differenc-
es in types of procedures, physicians managing propofol, 
and various target levels of sedation, such as moderate-to-
deep sedation (MOAA/S scores 2--3 or BIS value 76--85)14 
and deep sedation (BIS values >55 or <55 were permit-
ted),16 and deep sedation (MOAA/S scores 0 or BIS value 
40--60).17 For propofol sedation in gastrointestinal endosco-
py, propofol should be administered by an anesthesiolo-
gist,17 or endoscopists or nursing staff14,16 who receive spe-
cial training in sedation and resuscitation techniques for 
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gianni A, et al. Auditory evoked potentials compared with bispec-
tral index for monitoring of midazolam and propofol sedation dur-
ing colonoscopy. Am J Gastroenterol 2009;104:318-25.
20. Johansen JW. Update on bispectral index monitoring. Best Pract 
Res Clin Anaesthesiol 2006;20:81-99.
21. Park CH, Min JH, Yoo YC, Kim H, Joh DH, Jo JH, et al. Sedation 
methods can determine performance of endoscopic submucosal 
dissection in patients with gastric neoplasia. Surg Endosc 2013;27: 
2760-7.
22. Park CH, Kim H, Kang YA, Cho IR, Kim B, Heo SJ, et al. Risk 
factors and prognosis of pulmonary complications after endoscop-
ic submucosal dissection for gastric neoplasia. Dig Dis Sci 2013; 
58:540-6.
23. Knape JT, Adriaensen H, van Aken H, Blunnie WP, Carlsson C, 
Dupont M, et al. Guidelines for sedation and/or analgesia by non-
anaesthesiology doctors. Eur J Anaesthesiol 2007;24:563-7.
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25. Bouillon TW, Bruhn J, Radulescu L, Andresen C, Shafer TJ, Co-
hane C, et al. Pharmacodynamic interaction between propofol and 
remifentanil regarding hypnosis, tolerance of laryngoscopy, 
using an infusion pump according to the patient’s weight. 
However, these drugs should optimally be administered us-
ing target-controlled infusion systems considering several 
factors affecting the pharmacokinetics-pharmacodynamics 
of propofol and remifentanil, such as the age, weight, height, 
and underlying disease, especially in lengthy procedures.30 
Therefore, further study is needed to evaluate the efficacy 
of BIS monitoring considering these limitations. 
In conclusion, BIS-guided propofol infusion combined 
with remifentanil reduced the number of patients requiring 
rescue propofol in ESD procedures. However, this finding 
did not lead to a reduction in the total dose of propofol or the 
rate of complications, and thus, BIS monitoring is of limit-
ed use in the guidance of sedation in the setting of continu-
ous propofol infusion with remifentanil managed by an an-
esthesiologist.
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